Show simple item record

dc.contributor.authorPerez-Vazquez, Maria 
dc.contributor.authorOteo-Iglesias, Jesus 
dc.contributor.authorSola-Campoy, Pedro Juan 
dc.contributor.authorCarrizo-Manzoni, Hugo
dc.contributor.authorBautista, Veronica 
dc.contributor.authorLara Fuella, Noelia 
dc.contributor.authorAracil, Belen 
dc.contributor.authorAlhambra, Almudena
dc.contributor.authorMartínez-Martínez, Luis
dc.contributor.authorCampos, Jose
dc.identifier.citationAntimicrob Agents Chemother . 2019 May 24;63(6):e02529-18.es_ES
dc.description.abstractThere is little information about carbapenemase-producing (CP) Klebsiella oxytoca, an important nosocomial pathogen. We characterized CP K. oxytoca isolates collected from different Spanish hospitals between January 2016 and October 2017. During the study period, 139 nonduplicate CP K. oxytoca isolates were identified; of these, 80 were studied in detail. Carbapenemase and extended-spectrum β-lactamase genes were identified by PCR and sequencing. Genetic relatedness was studied by pulsed-field gel electrophoresis (PFGE). Whole-genome sequencing (WGS), carried out on 12 representative isolates, was used to identify the resistome, to elucidate the phylogeny, and to determine the plasmids harboring carbapenemase genes. Forty-eight (60%) isolates produced VIM-1, 30 (37.5%) produced OXA-48, 3 (3.7%) produced KPC-2, 2 (2.5%) produced KPC-3, and 1 (1.2%) produced NDM-1; 4 isolates coproduced two carbapenemases. By PFGE, 69 patterns were obtained from the 80 CP K. oxytoca isolates, and four well-defined clusters were detected: cluster 1 consisted of 11 OXA-48-producing isolates, and the other three clusters included VIM-1-producing isolates (5, 3, and 3 isolates, respectively). In the 12 sequenced isolates, the average number of acquired resistance genes was significantly higher in VIM-1-producing isolates (10.8) than in OXA-48-producing isolates (2.3). All 12 isolates had chromosomally encoded genes of the blaOXY-2 genotype, and by multilocus sequence typing, most belonged to sequence type 2 (ST2). Carbapenemase genes were carried by IncL, IncHI2, IncFII, IncN, IncC, and IncP6 plasmid types. The emergence of CP K. oxytoca was principally due to the spread of VIM-1- and OXA-48-producing isolates in which VIM-1- and OXA-48 were carried by IncL, IncHI2, IncFII, and IncN plasmids. ST2 and the genotype blaOXY-2 predominated among the 12 sequenced isolates.es_ES
dc.description.sponsorshipThis work was supported by Plan Nacional de I+D+i 2013-2016 and the Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Ciencia, Innovación y Universidades, Spanish Network for Research in Infectious Diseases (REIPI RD16CIII/0004/0002, RD16/0016/0008), cofinanced by the European Development Regional Fund ERDF (A way to achieve Europe) operative program Intelligent Growth 2014-2020. This work was also supported by a grant from the Instituto de Salud Carlos III (grant number MPY 1135/16) and by the Antibiotic Resistance Surveillance Program of the Centro Nacional de Microbiología (Instituto de Salud Carlos III, Ministerio de Economía y Competitividad) of Spain.es_ES
dc.publisherAmerican Society for Microbiology (ASM) es_ES
dc.subjectKlebsiella oxytocaes_ES
dc.subjectWhole-genome sequencinges_ES
dc.subject.meshBacterial Proteins es_ES
dc.subject.meshDrug Resistance, Multiple, Bacterial es_ES
dc.subject.meshElectrophoresis, Gel, Pulsed-Field es_ES
dc.subject.meshHumans es_ES
dc.subject.meshKlebsiella oxytoca es_ES
dc.subject.meshMicrobial Sensitivity Tests es_ES
dc.subject.meshMultilocus Sequence Typing es_ES
dc.subject.meshPlasmids es_ES
dc.subject.meshSpain es_ES
dc.subject.meshbeta-Lactamases es_ES
dc.titleCharacterization of Carbapenemase-Producing Klebsiella oxytoca in Spain, 2016-2017.es_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución-NoComercial-CompartirIgual 4.0 Internacional*
dc.contributor.funderInstituto de Salud Carlos III 
dc.contributor.funderRETICS-Investigación en Patología Infecciosa (REIPI-ISCIII) (España) 
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) 
dc.identifier.journalAntimicrobial agents and chemotherapyes_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/REIPI RD16CIII/0004/0002es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/MPY 1135/16es_ES
dc.rights.accessRightsopen accesses_ES

Files in this item

Acceso Abierto

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-CompartirIgual 4.0 Internacional
This item is licensed under a: Atribución-NoComercial-CompartirIgual 4.0 Internacional